Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Change in Account Payables: 2018-2024

Historic Change in Account Payables for Fulcrum Therapeutics (FULC) over the last 7 years, with Dec 2024 value amounting to -$1.6 million.

  • Fulcrum Therapeutics' Change in Account Payables rose 218.52% to $946,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 million, marking a year-over-year decrease of 505.57%. This contributed to the annual value of -$1.6 million for FY2024, which is 86.75% down from last year.
  • As of FY2024, Fulcrum Therapeutics' Change in Account Payables stood at -$1.6 million, which was down 86.75% from -$853,000 recorded in FY2023.
  • Over the past 5 years, Fulcrum Therapeutics' Change in Account Payables peaked at $1.8 million during FY2020, and registered a low of -$1.6 million during FY2024.
  • In the last 3 years, Fulcrum Therapeutics' Change in Account Payables had a median value of -$1.2 million in 2022 and averaged -$1.2 million.
  • As far as peak fluctuations go, Fulcrum Therapeutics' Change in Account Payables skyrocketed by 120.80% in 2020, and later slumped by 220.86% in 2022.
  • Over the past 5 years, Fulcrum Therapeutics' Change in Account Payables (Yearly) stood at $1.8 million in 2020, then slumped by 45.12% to $973,000 in 2021, then slumped by 220.86% to -$1.2 million in 2022, then rose by 27.47% to -$853,000 in 2023, then slumped by 86.75% to -$1.6 million in 2024.